Frappaz, D., Barritault, M., Montané, L., Laigle-Donadey, F., Chinot, O., Le Rhun, E., . . . Pérol, D. (2019). OS4.1 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway. Neuro Oncol.
Citação norma ChicagoFrappaz, D., et al. "OS4.1 MEVITEM: A European, Randomized, Open-label, Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastoma Presenting an Activation of the Sonic Hedgehog (SHH) Pathway." Neuro Oncol 2019.
MLA citiranjeFrappaz, D., et al. "OS4.1 MEVITEM: A European, Randomized, Open-label, Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastoma Presenting an Activation of the Sonic Hedgehog (SHH) Pathway." Neuro Oncol 2019.